<p>随着美国股市创下新高，标准普尔 500 指数收于历史最高水平，科技股引领近期涨幅，投资者密切关注高增长行业的潜在机会。在这种环境下，识别强劲的科技股需要考虑它们在不断变化的经济条件下的创新能力和韧性。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>HubSpot</td>
<td>14.28%</td>
<td>48.34%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Precigen</td>
<td>55.77%</td>
<td>79.70%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 73 只股票完整列表。</p>
<p>让我们深入探讨筛选器中的一些优质选择。</p>
<h2>Viant Technology (DSP)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Viant Technology Inc. 是一家广告技术公司，市值约为 7.4188 亿美元。</p>
<p><strong>运营：</strong> Viant Technology 主要通过其企业技术平台产生收入，该平台贡献了 3.2413 亿美元。公司专注于为客户提供广告技术解决方案。</p>
<p>Viant Technology 的战略举措，包括与 iHeartMedia 的显著整合以及与 Molson Coors 的合作，突显了其提升程序化广告和结果驱动策略的承诺。这从其年收入增长 13.3% 和年盈利增长 44.2% 中可见一斑，均超过美国市场平均水平。公司最近第三季度的销售额从去年 79.92 百万美元增加到 85.58 百万美元，反映出其在竞争激烈的科技领域中成功执行商业模式。Viant 通过直接访问等举措专注于与出版商的直接关系，进一步将其定位为连接电视（CTV）和数字广告领域的创新者，利用先进技术优化广告支出效率和效果。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Viant Technology 的动态。</li>
<li>了解 Viant Technology 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 DSP 收入和支出细分</p>
<h2>Dynavax Technologies (DVAX)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Dynavax Technologies Corporation 是一家商业阶段的生物制药公司，专注于在美国和国际上开发和商业化疫苗，市值约为 13.1 亿美元。</p>
<p><strong>运营：</strong> Dynavax Technologies 专注于新型疫苗的发现、开发和商业化，收入为 3.3051 亿美元。公司在生物制药领域运营，主要强调疫苗创新和国内外分销。</p>
<p>在变革阶段的 Dynavax Technologies 显示出强劲的财务和运营增长，最近被赛诺菲以 19 亿美元收购，表明市场信心强劲。这一战略举措得到了年度盈利增长 52.76% 的显著预测和季度收入从 8063 万美元跃升至 9488 万美元的令人印象深刻的增长的支持。公司的创新承诺在其研发项目中显而易见，例如 Z-1018 带状疱疹疫苗，与已建立的产品竞争，展示了 Dynavax 对公共健康的重大影响潜力。</p>
<ul>
<li>点击这里发现 Dynavax Technologies 的细微差别，查看我们的详细分析健康报告。</li>
<li>查看我们的历史表现报告，以获取对 Dynavax Technologies 过去表现的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 DVAX 收入和支出细分</p>
<h2>Phreesia (PHR)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Phreesia, Inc. 提供一个集成的基于 SaaS 的软件和支付平台，专为美国和加拿大的医疗行业量身定制，市值约为 9.9293 亿美元。</p>
<p><strong>运营：</strong> Phreesia 主要通过其技术解决方案部门产生收入，该部门占 463.21 百万美元。</p>
<p>Phreesia 展现了显著的扭转，从最近的季度报告中显示出从净亏损 1440 万美元转变为净收入 427 万美元，反映出显著的运营改善和有效的成本管理。这一转变得到了年度收入增长 10.7% 的支持，使公司在竞争激烈的科技领域中处于良好位置。进一步增强投资者信心的是，Phreesia 将其 2026 财年的收入预测提高至 4.79 亿至 4.81 亿美元，表明持续的增长势头和战略业务扩展，例如预计将贡献额外 750 万美元收入的 AccessOne 整合。这种在预测和适应市场需求方面的积极做法表明 Phreesia 在高科技解决方案中的持续扩展前景良好。</p>
<ul>
<li>点击以探索我们在 Phreesia 健康报告中的详细发现。</li>
<li>通过我们的详细历史表现报告评估 Phreesia 的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown"/></p>
<p>PHR 收入和支出明细截至 2025 年 12 月</p>
<h2>让它发生</h2>
<ul>
<li>点击这里深入了解 73 只美国高增长科技和人工智能股票的世界。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时获取股票的任何重要更新。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，并获取各市场无与伦比的股票分析。</li>
</ul>
<h2>准备好不同的方法了吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>用于国防和灾难的移动基础设施</p>
<p>下一波机器人技术不是类人机器人。它是能够在 30 分钟内提供 5G、ISR 和雷达的全自动塔，适用于任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>代表 CiTech 赞助</p>

PLTR

<p>美国股市正在创下新高，科技股领涨。投资者正在关注高增长领域的机会。顶尖科技公司如 Marker Therapeutics、Palantir 和 Workday 显示出显著的收入和盈利增长。Viant Technology、Dynavax Technologies 和 Phreesia 因其战略举措和财务增长而受到关注。Viant 专注于广告技术，Dynavax 专注于疫苗，Phreesia 专注于医疗软件。文章鼓励探索 73 只高增长的科技和人工智能股票，以寻找潜在的投资机会</p>

<p>As the U.S. stock market reaches new highs with the S&amp;P 500 closing at a record level and tech stocks leading recent gains, investors are closely watching high-growth sectors for potential opportunities. In this environment, identifying strong tech stocks involves considering their capacity for innovation and resilience amid evolving economic conditions.</p>
<div class="lb-trans"><p>随着美国股市创下新高，标准普尔 500 指数收于历史最高水平，科技股引领近期涨幅，投资者密切关注高增长行业的潜在机会。在这种环境下，识别强劲的科技股需要考虑它们在不断变化的经济条件下的创新能力和韧性。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>HubSpot</td>
<td>14.28%</td>
<td>48.34%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Precigen</td>
<td>55.77%</td>
<td>79.70%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>HubSpot</td>
<td>14.28%</td>
<td>48.34%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Precigen</td>
<td>55.77%</td>
<td>79.70%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 73 只股票完整列表。</p>
</div><p>Let's dive into some prime choices out of from the screener.</p>
<div class="lb-trans"><p>让我们深入探讨筛选器中的一些优质选择。</p>
</div><h2>Viant Technology (DSP)</h2>
<div class="lb-trans"><h2>Viant Technology (DSP)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Viant Technology Inc. is an advertising technology company with a market capitalization of approximately $741.88 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Viant Technology Inc. 是一家广告技术公司，市值约为 7.4188 亿美元。</p>
</div><p><strong>Operations:</strong> Viant Technology generates revenue primarily through its Enterprise Technology Platform, which contributed $324.13 million. The company focuses on providing advertising technology solutions to its clients.</p>
<div class="lb-trans"><p><strong>运营：</strong> Viant Technology 主要通过其企业技术平台产生收入，该平台贡献了 3.2413 亿美元。公司专注于为客户提供广告技术解决方案。</p>
</div><p>Viant Technology's strategic moves, including a notable integration with iHeartMedia and partnerships like the one with Molson Coors, underscore its commitment to enhancing programmatic advertising and outcome-driven strategies. This is evident from its 13.3% annual revenue growth and robust earnings growth of 44.2% per year, outpacing the US market average. The company's recent third-quarter sales increase to $85.58 million from $79.92 million the previous year reflects a solid execution of its business model in a competitive tech landscape. Viant's focus on direct publisher relationships through initiatives like Direct Access further positions it as an innovator in connected TV (CTV) and digital advertising spaces, leveraging advanced technology to optimize ad spending efficiency and effectiveness.</p>
<div class="lb-trans"><p>Viant Technology 的战略举措，包括与 iHeartMedia 的显著整合以及与 Molson Coors 的合作，突显了其提升程序化广告和结果驱动策略的承诺。这从其年收入增长 13.3% 和年盈利增长 44.2% 中可见一斑，均超过美国市场平均水平。公司最近第三季度的销售额从去年 79.92 百万美元增加到 85.58 百万美元，反映出其在竞争激烈的科技领域中成功执行商业模式。Viant 通过直接访问等举措专注于与出版商的直接关系，进一步将其定位为连接电视（CTV）和数字广告领域的创新者，利用先进技术优化广告支出效率和效果。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Viant Technology.</li>
<li>Learn about Viant Technology's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Viant Technology 的动态。</li>
<li>了解 Viant Technology 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown"/></p>
<p>DSP Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 DSP 收入和支出细分</p>
</div><h2>Dynavax Technologies (DVAX)</h2>
<div class="lb-trans"><h2>Dynavax Technologies (DVAX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that specializes in developing and commercializing vaccines both in the United States and internationally, with a market cap of approximately $1.31 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dynavax Technologies Corporation 是一家商业阶段的生物制药公司，专注于在美国和国际上开发和商业化疫苗，市值约为 13.1 亿美元。</p>
</div><p><strong>Operations:</strong> Dynavax Technologies focuses on the discovery, development, and commercialization of novel vaccines, generating revenue of $330.51 million. The company operates in the biopharmaceutical sector with a primary emphasis on vaccine innovation and distribution both domestically and internationally.</p>
<div class="lb-trans"><p><strong>运营：</strong> Dynavax Technologies 专注于新型疫苗的发现、开发和商业化，收入为 3.3051 亿美元。公司在生物制药领域运营，主要强调疫苗创新和国内外分销。</p>
</div><p>Dynavax Technologies, amid a transformative phase, has shown robust financial and operational growth with its recent acquisition by Sanofi for $1.9 billion, signaling strong market confidence. This strategic move is complemented by a significant 52.76% forecast in annual earnings growth and an impressive jump in quarterly revenue from $80.63 million to $94.88 million year-over-year. The firm's commitment to innovation is evident from its R&amp;D initiatives like the Z-1018 shingles vaccine, which competes closely with established products, showcasing Dynavax's potential to impact public health significantly.</p>
<div class="lb-trans"><p>在变革阶段的 Dynavax Technologies 显示出强劲的财务和运营增长，最近被赛诺菲以 19 亿美元收购，表明市场信心强劲。这一战略举措得到了年度盈利增长 52.76% 的显著预测和季度收入从 8063 万美元跃升至 9488 万美元的令人印象深刻的增长的支持。公司的创新承诺在其研发项目中显而易见，例如 Z-1018 带状疱疹疫苗，与已建立的产品竞争，展示了 Dynavax 对公共健康的重大影响潜力。</p>
</div><ul>
<li>Click here to discover the nuances of Dynavax Technologies with our detailed analytical health report.</li>
<li>Review our historical performance report to gain insights into Dynavax Technologies''s past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里发现 Dynavax Technologies 的细微差别，查看我们的详细分析健康报告。</li>
<li>查看我们的历史表现报告，以获取对 Dynavax Technologies 过去表现的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown"/></p>
<p>DVAX Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 DVAX 收入和支出细分</p>
</div><h2>Phreesia (PHR)</h2>
<div class="lb-trans"><h2>Phreesia (PHR)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Phreesia, Inc. offers an integrated SaaS-based software and payment platform tailored for the healthcare industry across the United States and Canada, with a market cap of approximately $992.93 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Phreesia, Inc. 提供一个集成的基于 SaaS 的软件和支付平台，专为美国和加拿大的医疗行业量身定制，市值约为 9.9293 亿美元。</p>
</div><p><strong>Operations:</strong> Phreesia generates revenue primarily from its Technology Solutions segment, which accounted for $463.21 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Phreesia 主要通过其技术解决方案部门产生收入，该部门占 463.21 百万美元。</p>
</div><p>Phreesia has demonstrated a notable turnaround, transitioning from a net loss of $14.4 million to a net income of $4.27 million in its recent quarterly report, reflecting significant operational improvements and effective cost management. This shift is underscored by an impressive 10.7% annual revenue growth, positioning the company well within the competitive tech landscape. Further bolstering investor confidence, Phreesia has raised its fiscal 2026 revenue forecast to between $479 million and $481 million, indicative of sustained growth momentum and strategic business expansions such as the AccessOne integration expected to contribute an additional $7.5 million in revenue. This proactive approach in forecasting and adapting to market demands suggests promising prospects for Phreesia's continued expansion in high-tech solutions.</p>
<div class="lb-trans"><p>Phreesia 展现了显著的扭转，从最近的季度报告中显示出从净亏损 1440 万美元转变为净收入 427 万美元，反映出显著的运营改善和有效的成本管理。这一转变得到了年度收入增长 10.7% 的支持，使公司在竞争激烈的科技领域中处于良好位置。进一步增强投资者信心的是，Phreesia 将其 2026 财年的收入预测提高至 4.79 亿至 4.81 亿美元，表明持续的增长势头和战略业务扩展，例如预计将贡献额外 750 万美元收入的 AccessOne 整合。这种在预测和适应市场需求方面的积极做法表明 Phreesia 在高科技解决方案中的持续扩展前景良好。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Phreesia's health report.</li>
<li>Assess Phreesia's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击以探索我们在 Phreesia 健康报告中的详细发现。</li>
<li>通过我们的详细历史表现报告评估 Phreesia 的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown"/></p>
<p>PHR Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>PHR 收入和支出明细截至 2025 年 12 月</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>让它发生</h2>
</div><ul>
<li>Gain an insight into the universe of 73 US High Growth Tech and AI Stocks by clicking here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 73 只美国高增长科技和人工智能股票的世界。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时获取股票的任何重要更新。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，并获取各市场无与伦比的股票分析。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好不同的方法了吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用于国防和灾难的移动基础设施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人。它是能够在 30 分钟内提供 5G、ISR 和雷达的全自动塔，适用于任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 赞助</p>
</div>

Exploring US High Growth Tech Stocks for Potential Expansion

- 美股市场创下新高，S&P 500 达历史最高位。
- 投资者关注高增长行业，以寻找潜在机会。
- 高增长科技公司的收入和盈利增长显著，例如 Viant 和 Dynavax。

探索美国高增长科技股的扩展潜力